. home.aspx

home.aspx
   

RNA Targeting Poised To Share The Spotlight With Gene Therapy

January 16, 2020 / DANIEL CHANCELLOR

As the biopharma industry concludes its annual pilgrimage to San Francisco for the JP Morgan investor conference, much of the talk around town inevitably was about gene therapies. Rightfully so, considering the therapeutic promise of such one-time cures, and the spate of M&A activity for gene therapy biotechs and manufacturers, despite justifiable concerns over its scalability and affordability. Spotlighting this technological advance and its impending transition from the clinic to doctors’ offices seems appropriate as we start a new decade. However, rather than add to the increasing column inches surrounding gene therapy, this article looks at drugs that target RNA, either through double-stranded RNA-mediated interference (RNAi) or antisense oligonucleotides (ASOs). Arguably overshadowed by gene therapies and their curative hype, RNA therapeutics are gaining prominence,